SavedAdd your journal

Journals / Van Sağlık Bilimleri Dergisi / 2000 / Cilt: 6 Sayı: 1-2 - 2000

Lipoprotein a , plasma cholinesterase and other risk factors in patients with type 2 diabetes mellitus

Tip 2 diabetik hastalarda lipoprotein a , plazma kolinesteraz ve diğer risk faktörleri

M. Ramazan ŞEKEROĞLU
Selim TOPAL
Ekrem ALGÜN
Mehmet TARAKÇIOĞLU
Haluk DÜLGER
Pages
1–4
Publication Date
2000-06-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cholinesterase. apo B. triglyceride, glucose and Hb Aıc values of diabetic group were higher than those of the control group p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The serum Lipoprotein a [Lp a J concentration is an independent risk factor for atherosclerosis.
📊
Key Findings & Data:Thirty patients with type 2 diabetes mellitus age: range 40-63 years; mean 51.9 years , and 30 healthy Controls age: range 40-58 years; mean 49.7 years participated in this study.
💡
Conclusion & Impact:Cholinesterase. apo B. triglyceride, glucose and Hb Aıc values of diabetic group were higher than those of the control group p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes mellitus · Lp(a) · kolinesteraz

Abstract

The serum Lipoprotein a [Lp a J concentration is an independent risk factor for atherosclerosis. Atherosclerosis is the most common cause of death in diabetic patients. Thirty patients with type 2 diabetes mellitus age: range 40-63 years; mean 51.9 years , and 30 healthy Controls age: range 40-58 years; mean 49.7 years participated in this study. The levels of Lp a , glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, apo A, apo B. HbAıc and cholinesterase activity in both groups were determined. Cholinesterase. apo B. triglyceride, glucose and Hb Aıc values of diabetic group were higher than those of the control group p

Özet

Serum Lipoprotein a [Lp a ] konsantrasyonu ateroskleroz için bağımsız bir risk faktörü olarak kabul edilmektedir. Ateroskleroz da diabetik hastalarda ölümün en yaygın sebebidir. Bu çalışma 30 sağlıklı kontrol ortalama yaş: 49.7 yıl ile glisemik kontrol altında olan 30 tip 2 diabetes mellituslu hastada ortalama yaş:51.9 yıl gerçekleştirildi. Her iki grupta da Lp a , glukoz, total kolesterol, HDL-kolesterol. LDL-kolesterol, trigliserid, Apo Al, Apo B ve HbAlC seviyeleri ile kolinesteraz aktivitesi saptandı. Diabetik grupta kolinesteraz. apo B, trigliserid, glukoz ve HbAlC seviyeleri kontrol grubundan yüksekti p

🔖

Cite This Article

ŞEKEROĞLU, M. R., TOPAL, S., ALGÜN, E., TARAKÇIOĞLU, M., DÜLGER, H. (2000). Lipoprotein a , plasma cholinesterase and other risk factors in patients with type 2 diabetes mellitus. Van Sağlık Bilimleri Dergisi, Cilt: 6 Sayı: 1-2 - 2000, 1–4. https://ajindex.com/articles/953026

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Türkmen F, Akkuş İ, Büyükbaş S, Çığlı A: Diyabetes mellitusta biyokimyasal değişiklikler ve komplikasyonlar. T Klin Tıp Bilimleri 10(1): 1-10, (1990). Dunn FL. Hiperlipidemia and diabetes. Med Clin North Am 66(6): 1347- 1360, (1982).
  2. Gaııbatz JW, Heideman C, Gotto AM, Moırisett JD, Dahlen GH: Isolation and characteıisation of the two majör apoproteins in human lipoprotein (a). J Biol Chem 258: 4582-4589, (1983).
  3. Mc Clean JA, Tomlihson J, Kuang WJ, Eaton D, Chen E, Flees G, Scanu A, Lawn R: DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330: 132-137, (1987).
  4. Hajjar AA, Gawish D, Breslow JL. Nachman RL: Lipoprotein (a) modıılation of endothelial celi surface fıbrinolysis and its potential role in atherosclerosis. Nature 39: 303-330. (1989). Uterman G: Lipoprotein (a): a genetic risk factor for prematüre coronary heart disease. Curr Opin Lipidol 1: 404-410, (1989).
  5. Koster GM, Avogaro P, Cazzolato G, Maıth E, Bittolo-Bon G, Qunici GB: Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis 38:51-61,(1981).
  6. Guillausseau PJ, Peynet J. Chanson P, Legıand A, Altmann JJ, Poupon JN, Guyen M, Rousselet F: Lipoprotein (a) in diabetic patients with and without chronic renal failure. Diabetes Çare 15(8): 976-979, (1992).
  7. Bıucket E, Davidooff P, Grimaldi A, Truffert G, Giıal P, Doumitou R. Teı vet F, Degennes JI: Increased serum levels of lipoprotein (a) in diabetes mellitus and their reduction with glicemic control. J Am Med Assoc 263: 35-36, (1990).
  8. Ritter M.M, Coscar M, Richter US, Schwandt P: Lipoprotein (a) in diabetes mellitus. Clin Chim Açta 214: 45-54, (1993).
  9. Haffner SM, Morales, PA, S tem MP, Gıuber MK: Lp (a) concentıations in NIDDM Diabetes 41: 1267-1272,(1992).
  10. Taupin JM, Durlach V, Hassaim M, Giller P, Jolly D, Boirie Y, Grulet H, Leutenegger M: Lipoprotein (a) and diabetes, relationship based on 224 cases. Diabet Metab 19(2): 250-256, (1993). Kostner GM: Standardization of Lp (a) Assay (letter). Clin Chim Açta 21 1: 191 -194, (1992). Kutty KM. Jain R. Huang SN: Serum pseudo-cholinesterase; High densty lipoprotein cholesteıol as an index of risk for caıdiovascular disease. Clin Chim Açta 115: 55-61, (1981).
  11. Jain R, Kutty KM, Huang SN: Pseudocholinesteıase; High densty lipoprotein cholesteıol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 29: 1301-1033, (1983).
  12. Ragaobirsingh D, Bharaj BS. Morrison RY: Change in serum cholinesterase activity in Jamaican diabetics. J Natl Med Assoc 84: 8